Trials / Completed
CompletedNCT03386851
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
Post-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia or Bipolar 1 Disorder Under the "New Drug Re-Examination"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,030 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a Post-Marketing Surveillance (PMS) of Abilify Maintena® Injections in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: Ministry of Food and Drug Safety(MFDS) Notification).
Conditions
Timeline
- Start date
- 2016-12-13
- Primary completion
- 2021-05-25
- Completion
- 2021-05-25
- First posted
- 2017-12-29
- Last updated
- 2022-02-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03386851. Inclusion in this directory is not an endorsement.